Literature DB >> 16357307

Compartmentalized phosphodiesterase-2 activity blunts beta-adrenergic cardiac inotropy via an NO/cGMP-dependent pathway.

Marco Mongillo1, Carlo G Tocchetti, Anna Terrin, Valentina Lissandron, York-Fong Cheung, Wolfgang R Dostmann, Tullio Pozzan, David A Kass, Nazareno Paolocci, Miles D Houslay, Manuela Zaccolo.   

Abstract

beta-Adrenergic signaling via cAMP generation and PKA activation mediates the positive inotropic effect of catecholamines on heart cells. Given the large diversity of protein kinase A targets within cardiac cells, a precisely regulated and confined activity of such signaling pathway is essential for specificity of response. Phosphodiesterases (PDEs) are the only route for degrading cAMP and are thus poised to regulate intracellular cAMP gradients. Their spatial confinement to discrete compartments and functional coupling to individual receptors provides an efficient way to control local [cAMP]i in a stimulus-specific manner. By performing real-time imaging of cyclic nucleotides in living ventriculocytes we identify a prominent role of PDE2 in selectively shaping the cAMP response to catecholamines via a pathway involving beta3-adrenergic receptors, NO generation and cGMP production. In cardiac myocytes, PDE2, being tightly coupled to the pool of adenylyl cyclases activated by beta-adrenergic receptor stimulation, coordinates cGMP and cAMP signaling in a novel feedback control loop of the beta-adrenergic pathway. In this, activation of beta3-adrenergic receptors counteracts cAMP generation obtained via stimulation of beta1/beta2-adrenoceptors. Our study illustrates the key role of compartmentalized PDE2 in the control of catecholamine-generated cAMP and furthers our understanding of localized cAMP signaling.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16357307     DOI: 10.1161/01.RES.0000200178.34179.93

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  109 in total

Review 1.  Phosphodiesterase function and endocrine cells: links to human disease and roles in tumor development and treatment.

Authors:  Isaac Levy; Anelia Horvath; Monalisa Azevedo; Rodrigo Bertollo de Alexandre; Constantine A Stratakis
Journal:  Curr Opin Pharmacol       Date:  2011-10-31       Impact factor: 5.547

2.  Ca(2+)-stimulated adenylyl cyclases regulate the L-type Ca(2+) current in guinea-pig atrial myocytes.

Authors:  Thomas P Collins; Derek A Terrar
Journal:  J Physiol       Date:  2012-02-20       Impact factor: 5.182

3.  Equilibrium between adenylyl cyclase and phosphodiesterase patterns adrenergic agonist dose-dependent spatiotemporal cAMP/protein kinase A activities in cardiomyocytes.

Authors:  Vania De Arcangelis; Shubai Liu; Dawen Zhang; Dagoberto Soto; Yang K Xiang
Journal:  Mol Pharmacol       Date:  2010-06-07       Impact factor: 4.436

Review 4.  Advances in targeting cyclic nucleotide phosphodiesterases.

Authors:  Donald H Maurice; Hengming Ke; Faiyaz Ahmad; Yousheng Wang; Jay Chung; Vincent C Manganiello
Journal:  Nat Rev Drug Discov       Date:  2014-04       Impact factor: 84.694

5.  Attenuated response of L-type calcium current to nitric oxide in atrial fibrillation.

Authors:  Nadiia Rozmaritsa; Torsten Christ; David R Van Wagoner; Hannelore Haase; Johannes-Peter Stasch; Klaus Matschke; Ursula Ravens
Journal:  Cardiovasc Res       Date:  2013-12-12       Impact factor: 10.787

6.  A specific pattern of phosphodiesterases controls the cAMP signals generated by different Gs-coupled receptors in adult rat ventricular myocytes.

Authors:  Francesca Rochais; Aniella Abi-Gerges; Kathleen Horner; Florence Lefebvre; Dermot M F Cooper; Marco Conti; Rodolphe Fischmeister; Grégoire Vandecasteele
Journal:  Circ Res       Date:  2006-03-23       Impact factor: 17.367

7.  Interaction between phosphodiesterases in the regulation of the cardiac β-adrenergic pathway.

Authors:  Claire Y Zhao; Joseph L Greenstein; Raimond L Winslow
Journal:  J Mol Cell Cardiol       Date:  2015-09-23       Impact factor: 5.000

8.  Phosphodiesterase PDE2 activity, increased by isoprenaline, does not reduce β-adrenoceptor-mediated chronotropic and inotropic effects in rat heart.

Authors:  Alejandro Galindo-Tovar; María Luisa Vargas; Alberto J Kaumann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-03-19       Impact factor: 3.000

Review 9.  Therapeutic potential of PDE modulation in treating heart disease.

Authors:  Walter Knight; Chen Yan
Journal:  Future Med Chem       Date:  2013-09       Impact factor: 3.808

10.  Efficacy of B-Type Natriuretic Peptide Is Coupled to Phosphodiesterase 2A in Cardiac Sympathetic Neurons.

Authors:  Dan Li; Chieh-Ju Lu; Guoliang Hao; Hannah Wright; Lavinia Woodward; Kun Liu; Elisa Vergari; Nicoletta C Surdo; Neil Herring; Manuela Zaccolo; David J Paterson
Journal:  Hypertension       Date:  2015-04-27       Impact factor: 10.190

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.